[B026] 临床研究方案与设计

get
https://connect.zhihuiya.com/synapse/clinical-trial/design
在体验中心中试用

通过临床试验id或者登记号获取临床研究方案与设计

clinical_trial_id 和 register_number 两个参数必须传一个

请求参数

此 API 接口支持的参数列表

名称类型示例描述
clinical_trial_id
string202425a889e52ae802432a8295220e53
临床试验id,通过临床试验检索接口获取
register_number
stringNCT06498986
登记号

响应结构

API 响应数据的结构说明

字段名类型示例描述
data
object-
响应数据
masking
stringNone (Open Label)
盲法
outcome
array[ { "title": "Recommended Phase II Dose (RP2D)", "time_frame": "Up to approximately 24 months", "description": "The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.", "outcome_type": "Primary" }, { "title": "Objective response rate (ORR)", "time_frame": "Up to approximately 24 months", "description": "ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.", "outcome_type": "Primary" } ]
终点指标
title
stringRecommended Phase II Dose (RP2D)
指标
time_frame
stringUp to approximately 24 months
期限
description
stringThe RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.
详情
outcome_type
stringPrimary
指标类型
allocation
stringN/A
随机化
enrollment
array[ { "enrollment": "40" } ]
招募人数
location
stringDomestic
位置,Domestic:中国;International:国际
enrollment
string98
招募人数
enrollment_text
string国内:150
招募人数原始值
enrollment_type
stringAnticipated
招募类型
start_date
object{ "time_ts": 1722470400000, "date_type": "Anticipated" }
开始日期
time_ts
integer<int64>1785542400000
日期时间戳
date_type
stringAnticipated
日期类型,枚举值:Anticipated,Actual
study_type
stringInterventional
试验类型,枚举值:"Prevention","Expanded Access","Health Services Research","Interventional","Prognosis","Cause","Observational","Basic Science","Unknown","Others"
completion_date
object{ "time_ts": 1785542400000, "date_type": "Anticipated" }
试验完成日期
primary_purpose
stringTreatment
主要目的
register_number
stringNCT06498986
登记号
arm_intervention
array[ { "intervention": [ { "intervention_name": "BL-B01D1", "intervention_type": "Drug", "intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks." }, { "intervention_name": "Osimertinib Mesylate Tablets", "intervention_type": "Drug", "intervention_description": "Oral administration, 80mg daily for a cycle of 3 weeks." } ], "design_group_type": "Experimental", "design_group_title": "BL-B01D1+Osimertinib Mesylate Tablets", "design_group_description": "Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons." } ]
分组与干预
intervention
array[ { "intervention_name": "BL-B01D1", "intervention_type": "Drug", "intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks." }, { "intervention_name": "Osimertinib Mesylate Tablets", "intervention_type": "Drug", "intervention_description": "Oral administration, 80mg daily for a cycle of 3 weeks." } ]
干预
intervention_name
stringBL-B01D1
干预名称
intervention_type
stringDrug
干预类型
intervention_description
stringAdministration by intravenous infusion for a cycle of 3 weeks.
干预详情
design_group_type
stringExperimental
分组类型
design_group_title
stringBL-B01D1+Osimertinib Mesylate Tablets
分组标题
design_group_description
stringParticipants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
分组详情
clinical_trial_id
string202425a889e52ae802432a8295220e53
临床试验ID
first_posted_date
integer<int64>1720742400000
首次公示日期
intervention_model
stringSingle Group Assignment
设计类型
primary_completion_date
object{ "time_ts": 1785542400000, "date_type": "Anticipated" }
主要终点完成日期
status
必填
booleanfalse
状态
error_msg
stringThe request parameter format is incorrect!
错误信息
error_code
必填
integer0
错误代码

成功响应示例

成功调用 API 的响应示例

JSON
{
  "data": {
    "masking": "None (Open Label)",
    "outcome": [
      {
        "title": "Recommended Phase II Dose (RP2D)",
        "time_frame": "Up to approximately 24 months",
        "description": "The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.",
        "outcome_type": "Primary"
      }
    ],
    "allocation": "N/A",
    "enrollment": [
      {
        "location": "Domestic",
        "enrollment": 98,
        "enrollment_text": "国内:150",
        "enrollment_type": "Anticipated"
      }
    ],
    "start_date": {
      "time_ts": 1785542400000,
      "date_type": "Anticipated"
    },
    "study_type": "Interventional",
    "completion_date": {
      "time_ts": 1785542400000,
      "date_type": "Anticipated"
    },
    "primary_purpose": "Treatment",
    "register_number": "NCT06498986",
    "arm_intervention": [
      {
        "intervention": [
          {
            "intervention_name": "BL-B01D1",
            "intervention_type": "Drug",
            "intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks."
          }
        ],
        "design_group_type": "Experimental",
        "design_group_title": "BL-B01D1+Osimertinib Mesylate Tablets",
        "design_group_description": "Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons."
      }
    ],
    "clinical_trial_id": "202425a889e52ae802432a8295220e53",
    "first_posted_date": 1720742400000,
    "intervention_model": "Single Group Assignment",
    "primary_completion_date": {
      "time_ts": 1785542400000,
      "date_type": "Anticipated"
    }
  },
  "status": true,
  "error_code": 0
}

错误码

此接口可能返回的错误码列表

业务错误码

错误码描述
68300004请求参数异常!
68300005查询Api失败!
68300006解析基本存取错误!
68300007存在错误的请求!
68300008服务中断异常,请稍后再试!
68300010文件不符合上传规范!

平台错误码

错误码描述
67200001API整体限流错误!
67200002用户调用请求限流限制错误!
67200003申请token的key和secret不正确或者状态错误!
67200004无权限或该接口的套餐已超过系统设置的上限!
67200005账户余额不足,调用失败!
67200006客户端已过期,调用失败!
67200007超过调用额度,调用失败!

HTTP 状态码

状态码描述
0请求成功
401Unauthorized
403Forbidden
404Not Found

性能指标

此接口的预期性能特征

正常响应时间

5000 ms

最大响应时间

10000 ms